Ozone
CAS 10028-15-6
Ozone (CAS 10028-15-6) is a Phase 3 pharmaceutical compound with 0 bioactivity targets and 6 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPA1 TRPA1 |
Activation | 5.5 pEC50 | 20008466 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ozone used for in pharmaceutical contexts?
Ozone (CAS 10028-15-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ozone?
Ozone has 6 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cerebrovascular accident, Dementia, Dizziness, Gait disturbance, Headache. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ozone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for OZONE with EU status "permitted".
What clinical phase is Ozone in?
Ozone is rendered with ChEMBL max phase 3.